PMC9626235_01
Interval decrease in disease burden over one year period of olaparib administration, including hepatic dome lesion from 58x42 mm (a) to 24x18 mm (b); lower right paracolic gutter lesion from 108x66 mm (c) to complete response (d).
CRIOG2022-6579715.001.jpg
PMC9626235_01_CRIOG2022-6579715.001.jpg
fig1
At her 12-month surveillance visit, exam, and imaging was consistent with stable disease without evidence of interval progression (Figure 1).